Frasle Mobility S.A (FRAS3) Fair Value & Analysis
Consumer Cyclical · BR · Market cap R$6.0B
Analysis
Frasle Mobility S.A (FRAS3) currently trades at R$20.30, while our model-based Fair Value estimate is R$21.97 — implying the stock looks roughly 8.2% undervalued today. We read business quality at 95/100 (high quality), in the Consumer Cyclical sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Frasle Mobility S.A. provides friction materials for braking systems and other products in Brazil, England, Argentina, the United States, China, India, Uruguay, Holland, Chile, Colombia, Germany, South America, and internationally. It operates through Automakers and Replacement segments. The company offers brake linings for commercial vehicles, brake pads for commercial vehicles, automobiles, motorcycles and small aircraft, brake linings for automobiles, railway shoes, brake shoes for commercial vehicles and automobiles, clutch linings, molded linings, and universal plates and industrial products; brake disc, drum, master cylinder, servos, wheel cylinder, wheel hubs, repairs, actuators, and check valves. It also serves heavy vehicles, automobiles, motorcycles, rail, aviation, and agriculture sectors. The company sells its products under the FRAS-LE, Controil, FREMAX, and NAKATA brands. It also exports its products. The company was formerly known as Fras-le S.A. and changed its name …
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.